UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effects of the dual peroxisome proliferator–activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes

The American heart journal, 2015-07, Vol.170 (1), p.117-122

2015

Volltextzugriff (PDF)

Efficacy, Safety and Biomarker Data from SCarlet RoAD—a Global Phase 3 Study of Gantenerumab in Patients with Prodromal AD

The American journal of geriatric psychiatry, 2016-03, Vol.24 (3), p.S161-S162

2016

Volltextzugriff (PDF)

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial

JAMA : the journal of the American Medical Association, 2014-04, Vol.311 (15), p.1515

2014

Volltextzugriff (PDF)

Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non‐transfusion‐dependent β‐thalassaemia

British journal of haematology, 2021-07, Vol.194 (2), p.474-477

2021

Volltextzugriff (PDF)

Points to consider when initiating clinical investigations in autistic paediatric populations–A White Paper

European neuropsychopharmacology, 2024-09, Vol.86, p.35-42

2024

Volltextzugriff (PDF)

Efficacy, Safety and Biomarker Data from SCarlet RoAD - A Global Phase 3 Study of Gantenerumab in Patients with Prodromal AD (S1.002)

Neurology, 2016-04, Vol.86 (16_supplement)

2016

Volltextzugriff (PDF)

Phase 2 Clinical Trial Results for Bitopertin, an Oral Glycine Transporter 1 Inhibitor, in Patients with Non-Transfusion Dependent Beta-Thalassemia

Blood, 2018-11, Vol.132 (Supplement 1), p.3635-3635

2018

Volltextzugriff (PDF)

Poster Number: NR 31 - Efficacy, Safety and Biomarker Data from SCarlet RoAD—a Global Phase 3 Study of Gantenerumab in Patients with Prodromal AD

The American journal of geriatric psychiatry, 2016-03, Vol.24 (3), p.S161-S162

2016

Volltextzugriff (PDF)

O1‐10‐01: Gantenerumab Treatment Reduces Biomarkers of Neuronal and Synaptic Degeneration in Alzheimer’s Disease

Alzheimer's & dementia, 2016-07, Vol.12 (7S_Part_4), p.P198-P198

2016

Volltextzugriff (PDF)

GANTENERUMAB TREATMENT REDUCES BIOMARKERS OF NEURONAL AND SYNAPTIC DEGENERATION IN ALZHEIMER’S DISEASE

Alzheimer's & dementia, 2016-07, Vol.12 (7), p.P198-P198

2016

Volltextzugriff (PDF)

Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes: Diabetes and Metabolism

The American heart journal, 2015-07, Vol.170 (1), p.117-122

2015

Volltextzugriff (PDF)

CSF and amyloid pet biomarker data from scarlet road - a global Phase 3 study of gantenerumab in patients with prodromal AD

Neurobiology of aging, 2016-03, Vol.39, p.S28-S29

2016

Volltextzugriff (PDF)

Résultats d’efficacité, de tolérance et des biomarqueurs de SCarlet RoAD—une étude de phase 3 internationale du gantenerumab chez des patients atteints d’une maladie d’Alzheimer (MA) à la phase prodromale

Revue neurologique, 2016-04, Vol.172, p.A5-A5

2016

Volltextzugriff (PDF)

Efficacy and safety of gantenerumab in prodromal Alzheimer’s disease: Results from scarlet road—a global, multicenter trial

Alzheimer's & dementia, 2015-07, Vol.11 (7), p.P331-P332

2015

Volltextzugriff (PDF)

DT‐01‐03: Efficacy and safety of gantenerumab in prodromal Alzheimer's disease: Results from scarlet road—a global, multicenter trial

Alzheimer's & dementia, 2015-07, Vol.11 (7S_Part_7), p.P331-P332

2015

Volltextzugriff (PDF)

DT‐01‐02: Biomarker data from scarlet road: A global phase 3 study of gantenerumab in patients with prodromal Alzheimer's disease

Alzheimer's & dementia, 2015-07, Vol.11 (7S_Part_7), p.P331-P331

2015

Volltextzugriff (PDF)

Biomarker data from scarlet road: A global phase 3 study of gantenerumab in patients with prodromal Alzheimer's disease

Alzheimer's & dementia, 2015-07, Vol.11 (7), p.P331-P331

2015

Volltextzugriff (PDF)

Noninvasive Glucose Measurement by Monitoring of Scattering Coefficient During Oral Glucose Tolerance Tests

Diabetes technology & therapeutics, 2000, Vol.2 (2), p.211-220

2000

Volltextzugriff (PDF)

Spatial Modeling and Simulation of Diffusion in Nuclei of Living Cells

Computational Methods in Systems Biology, p.161-171

Volltextzugriff (PDF)

Genes Encoding Structural Proteins of Epidermal Cornification and S100 Calcium-Binding Proteins Form a Gene Complex (“Epidermal Differentiation Complex”) on Human Chromosome 1q21

Journal of investigative dermatology, 1996-05, Vol.106 (5), p.989-992

1996

Volltextzugriff (PDF)

Tetrahydrochromenoimidazoles as Potassium-Competitive Acid Blockers (P-CABs): Structure−Activity Relationship of Their Antisecretory Properties and Their Affinity toward the hERG Channel

Journal of medicinal chemistry, 2010-05, Vol.53 (9), p.3645-3674

2010

Volltextzugriff (PDF)

Matters of Communication - Formen und Materialitäten gestalteter Kommunikation

Sabine Foraita, Bianca Herlo, Axel Vogelsang / Axel Vogelsang, Sabine Foraita, Bianca Herlo

2020

Volltextzugriff (PDF)

Complex Transcription and Splicing of Odorant Receptor Genes

The Journal of biological chemistry, 2003-05, Vol.278 (22), p.19691-19701

2003

Volltextzugriff (PDF)

Genetic Analysis of the Epidermal Differentiation Complex (EDC) on Human Chromosome 1q21: Chromosomal Orientation, New Markers, and a 6-Mb YAC Contig

Genomics (San Diego, Calif.), 1996-11, Vol.37 (3), p.295-302

1996

Volltextzugriff (PDF)

Physical Mapping of a Functional Cluster of Epidermal Differentiation Genes on Chromosome 1q21

Genomics (San Diego, Calif.), 1993-10, Vol.18 (1), p.92-99

1993

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieInformation Processing & Management

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(24)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Effects of the dual peroxisome proliferator–activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes

Efficacy, Safety and Biomarker Data from SCarlet RoAD—a Global Phase 3 Study of Gantenerumab in Patients with Prodromal AD

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial

Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non‐transfusion‐dependent β‐thalassaemia

Points to consider when initiating clinical investigations in autistic paediatric populations–A White Paper

Efficacy, Safety and Biomarker Data from SCarlet RoAD - A Global Phase 3 Study of Gantenerumab in Patients with Prodromal AD (S1.002)

Phase 2 Clinical Trial Results for Bitopertin, an Oral Glycine Transporter 1 Inhibitor, in Patients with Non-Transfusion Dependent Beta-Thalassemia

Poster Number: NR 31 - Efficacy, Safety and Biomarker Data from SCarlet RoAD—a Global Phase 3 Study of Gantenerumab in Patients with Prodromal AD

O1‐10‐01: Gantenerumab Treatment Reduces Biomarkers of Neuronal and Synaptic Degeneration in Alzheimer’s Disease

GANTENERUMAB TREATMENT REDUCES BIOMARKERS OF NEURONAL AND SYNAPTIC DEGENERATION IN ALZHEIMER’S DISEASE

Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes: Diabetes and Metabolism

CSF and amyloid pet biomarker data from scarlet road - a global Phase 3 study of gantenerumab in patients with prodromal AD

Résultats d’efficacité, de tolérance et des biomarqueurs de SCarlet RoAD—une étude de phase 3 internationale du gantenerumab chez des patients atteints d’une maladie d’Alzheimer (MA) à la phase prodromale

Efficacy and safety of gantenerumab in prodromal Alzheimer’s disease: Results from scarlet road—a global, multicenter trial

DT‐01‐03: Efficacy and safety of gantenerumab in prodromal Alzheimer's disease: Results from scarlet road—a global, multicenter trial

DT‐01‐02: Biomarker data from scarlet road: A global phase 3 study of gantenerumab in patients with prodromal Alzheimer's disease

Biomarker data from scarlet road: A global phase 3 study of gantenerumab in patients with prodromal Alzheimer's disease

Noninvasive Glucose Measurement by Monitoring of Scattering Coefficient During Oral Glucose Tolerance Tests

Spatial Modeling and Simulation of Diffusion in Nuclei of Living Cells

Genes Encoding Structural Proteins of Epidermal Cornification and S100 Calcium-Binding Proteins Form a Gene Complex (“Epidermal Differentiation Complex”) on Human Chromosome 1q21

Tetrahydrochromenoimidazoles as Potassium-Competitive Acid Blockers (P-CABs): Structure−Activity Relationship of Their Antisecretory Properties and Their Affinity toward the hERG Channel

Matters of Communication - Formen und Materialitäten gestalteter Kommunikation

Complex Transcription and Splicing of Odorant Receptor Genes

Genetic Analysis of the Epidermal Differentiation Complex (EDC) on Human Chromosome 1q21: Chromosomal Orientation, New Markers, and a 6-Mb YAC Contig

Physical Mapping of a Functional Cluster of Epidermal Differentiation Genes on Chromosome 1q21

Aktive Filter

Suchergebnisse filtern